ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026
Global characterization of extrachromosomal circular DNA in cerebrospinal fluid of lung adenocarcinoma.
Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundNon-small cell lung cancer (NSCLC) is a particularly aggressive subtype of lung cancer characterized by early metastasis and poor prognosis. Lung adenocarcinoma (LUAD) represents the most prevalent histological subtype within NSCLC. The development of brain metastases in LUAD is frequently associated with a severely unfavorable outcome. While extrachromosomal circular DNA (eccDNA) has been implicated in various tumors, its specific role in brain metastasis related to LUAD remains largely unexplored.
methodsEccDNA associated with brain metastasis in LUAD profiles was collected through sequencing 20 cerebrospinal fluid (CSF) samples from both control subjects and LUAD patients with brain metastases, focusing on those with Epidermal Growth Factor Receptor (EGFR) mutations, rare mutations, or no mutations at all. The genomic characteristics of the eccDNAs were examined across groups utilizing a circular map. Differentially expressed eccDNAs were subjected to analysis and functional annotation by Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG), employing eccDNA-related genes.
resultsThe distribution of eccDNAs within the genome is intricately associated with gene density. We compared the genomic features of eccDNAs between the subtypes of control and brain metastatic LUAD. Differentially expressed eccDNAs in CSF were identified, and subsequent GO and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses demonstrated their functional relevance in each group.
conclusionsOur findings offer initial insights into the features of CSF-enriched eccDNAs across LUAD subtypes with varying pathogenic mechanisms, emphasizing their potential as diagnostic and prognostic indicators for LUAD.
Indexed as
Identifiers
42268565What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.